Kura launches with $60m to revive Janssen's tipifarnib

Kura Oncology raised $60m in a private placement and plans to complete a reverse merger into a public company to support Phase II clinical trials for tipifarnib, a drug for which Johnson & Johnson's Janssen subsidiary suspended development in multiple cancer indications in 2008.